Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b long-term intestinal effects of glepaglutide in short bowel syndrome
2020-005194-27Phase 3Completed
- Sponsor
- Zealand Pharma
- Start
- Jan 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3 trial of glepaglutide in short bowel syndrome (SBS), sponsored by Zealand Pharma. Primary endpoint: Absorption of wet weight/fluids. Started Jan 2021; status: completed.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on 2020-005194-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005194-27.